SNES senestech.com: Forward P/S Multiple

SenesTech, Inc. (SNES) generates revenue from the sale of ContraPest, an eco-friendly rodent birth control agent. However, the costs associated with bringing the product to market are creating a cash deficit and depleting reserves. The projected price-to-sales ratio visualizes this imbalance, where 1.70 captures the current state of the parameter. Cash flow stability remains low until the full commercial scaling of the technologies is achieved.

The forward P/S ratio determines the market value of a business relative to projected revenue, allowing investors to identify inflection points in the fundamental trend. Analysis of the forward P/S ratio captures capital overvaluation by institutional investors, which is critically important for SenesTech, Inc. (SNES), whose revenues from sustainable biotechnologies are protected by strict sanitary regulations and stable B2B demand regardless of macroeconomic fluctuations.